Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innate Pharma SA ( (FR:IPH) ) just unveiled an announcement.
Innate Pharma S.A. announced a €15 million investment from Sanofi, enhancing their ongoing partnership. This capital increase, involving the subscription of new shares by Sanofi, aims to support Innate’s pipeline execution and long-term value creation. The investment underscores Sanofi’s strategic interest in Innate’s innovative immunotherapy programs, potentially strengthening Innate’s market position and providing financial stability for future developments.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes innovative approaches to harness the innate immune system through multi-specific NK Cell Engagers, Antibody Drug Conjugates, and monoclonal antibodies. Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca to accelerate research and development.
YTD Price Performance: -50.0%
Average Trading Volume: 1,075
Technical Sentiment Signal: Strong Buy
Current Market Cap: $163.4M
Learn more about IPH stock on TipRanks’ Stock Analysis page.